SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10364)2/9/2004 11:42:41 AM
From: quidditch  Read Replies (2) | Respond to of 52153
 
Peter, a valuation question:

Why is NVGN responding to this news and not MSHL, which is a sub of NVGN. Is MSHL's license for ovarian cancer perceived to cover a too-narrow indication of Phenoxodiol? It seems that the Street sees leverage in this for the parent and not the sub, but that would not appear to be the case as a result of the license arrangement.

Clues?

quid



To: Biomaven who wrote (10364)2/24/2004 12:06:02 PM
From: quidditch  Read Replies (1) | Respond to of 52153
 
Peter,

What's going on with MSHL and NVGN that last couple of days. On Sunday, MSHL announced the commencement of a P1 trial (for the oral formulation) of phenoxodiol, and the market has punished both stocks ever since. Doesn't seem to make any sense.

I have no position, but I'm thinking about taking one. The values here are better now than a week ago, with no apparent change for the worse in fundamentals.

quid


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News